• Mira Pharmaceuticals on May 13, 2026 announced publication of peer-reviewed preclinical research on oral candidate SKNY-1, with results already presented in the journal article.
• Study reported SKNY-1 produced weight loss in an obesity-model zebrafish study without signs of harmful loss of body mass quality over the short treatment period.
• Researchers also described improvements in lipid-related measures, lower fat buildup in liver tissue, supported by shifts in appetite-related gene activity.
• Behavior tests showed reduced compulsive feeding and nicotine-seeking signals, supporting development rationale in obesity and nicotine addiction.
• Update did not disclose any new or upcoming human clinical trial timelines, leaving near-term value inflection tied to additional preclinical work or future clinical initiation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-022608), on May 13, 2026, and is solely responsible for the information contained therein.